Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Review ArticleReview

Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer

Meng Zhang, Ergang Liu, Yanna Cui and Yongzhuo Huang
Cancer Biology & Medicine August 2017, 14 (3) 212-227; DOI: https://doi.org/10.20892/j.issn.2095-3941.2017.0054
Meng Zhang
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
2University of Chinese Academy of Sciences, Beijing 100049, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ergang Liu
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
3State Key Laboratory of Chemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanna Cui
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
4Key Laboratory of Primate Neurobiology, Institute of Neuroscience, Chinese Academy of Sciences, Shanghai 200031, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongzhuo Huang
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
2University of Chinese Academy of Sciences, Beijing 100049, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yzhuang{at}simm.ac.cn
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Article Information

vol. 14 no. 3 212-227
DOI 
https://doi.org/10.20892/j.issn.2095-3941.2017.0054

Published By 
Cancer Biology & Medicine
History 
  • Received May 4, 2017
  • Accepted July 3, 2017
  • Published online August 1, 2017.

Copyright & Usage 
Copyright: © 2017, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

  1. Meng Zhang1,2,*,
  2. Ergang Liu1,3,*,
  3. Yanna Cui1,4 and
  4. Yongzhuo Huang⇑1,2
  1. 1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
  2. 2University of Chinese Academy of Sciences, Beijing 100049, China
  3. 3State Key Laboratory of Chemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
  4. 4Key Laboratory of Primate Neurobiology, Institute of Neuroscience, Chinese Academy of Sciences, Shanghai 200031, China
  1. Correspondence to: Yongzhuo Huang, E-mail: yzhuang{at}simm.ac.cn
View Full Text

Cited By...

  • 84 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Cancer Biology and Medicine: 14 (3)
Cancer Biology & Medicine
Vol. 14, Issue 3
1 Aug 2017
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
Meng Zhang, Ergang Liu, Yanna Cui, Yongzhuo Huang
Cancer Biology & Medicine Aug 2017, 14 (3) 212-227; DOI: 10.20892/j.issn.2095-3941.2017.0054

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
Meng Zhang, Ergang Liu, Yanna Cui, Yongzhuo Huang
Cancer Biology & Medicine Aug 2017, 14 (3) 212-227; DOI: 10.20892/j.issn.2095-3941.2017.0054
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Nanotechnology-based codelivery
    • Nanotechnology-based combination therapy
    • Prospects
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Gut microecology empowers cancer immunotherapy: commensal microbiota-mediated mechanisms and translational prospects of PD-1/PD-L1 therapy
  • Innovative cross-intervention: copper ions and metabolic pathways in cancer therapy
  • From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management
Show more Review

Similar Articles

Keywords

  • drug delivery
  • nanotechnology
  • multidrug resistance
  • combination therapy
  • cancer therapy

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire